Evaluating the role of the 620w allele of protein tyrosine phosphatase ptpn22 in crohn's disease and multiple sclerosis

ABSTRACT The 620W allele of PTPN22 has been associated with susceptibility to several different forms of chronic inflammatory disease, including Type 1 diabetes (T1D), rheumatoid arthritis

(RA), systemic lupus erythematosus (SLE), and autoimmune thyroiditis (AIT). We set out to explore its possible role in two other inflammatory diseases: multiple sclerosis (MS) and

Crohn's disease (CD). In our cohort of 496 MS trios from the United Kingdom, we observed reduced transmission of the PTPN22 620W allele. The CD sample consisted of 169 trios as well as

249 cases of CD with their 207 matched control subjects collected in the province of Québec, Canada; there was also no evidence of association between the PTPN22 620W allele and

susceptibility for CD. Pooled analyses combining our data with published data assessed a total of 1496 cases of MS and 1019 cases of CD but demonstrated no evidence of association with

either disease. Given the modest odds ratios of known risk alleles for inflammatory diseases, these analyses do not exclude a role for the PTPN22 allele in susceptibility to CD or MS, but

they do suggest that such a putative role would probably be more modest than that reported so far in T1D, RA, SLE, and AIT. SIMILAR CONTENT BEING VIEWED BY OTHERS MULTIPLE SCLEROSIS

SUSCEPTIBILITY MAY BE ASSOCIATED WITH THE CODING RS20541 (R130Q) _IL-13_ GENE POLYMORPHISM IN THE POLISH POPULATION Article Open access 12 December 2023 TOWARDS A GLOBAL VIEW OF MULTIPLE

SCLEROSIS GENETICS Article 08 September 2022 LACK OF ASSOCIATION OF THE PLD4 SNP RS2841277 WITH SYSTEMIC SCLEROSIS IN A EUROPEAN AMERICAN POPULATION Article Open access 28 December 2024

INTRODUCTION There has recently been interest in the 620W allele of the hematopoeitic-specific intracellular protein tyrosine phosphatase PTPN22 (OMIM# 600716). This allele is present at a

frequency of 8–16% in North American individuals of European descent.1, 2, 3, 4 The functional role of this R620W amino-acid substitution remains unclear at this time; _in vitro_, the

presence of the 620W allele decreases the binding affinity of an SH3 domain of the lymphoid-specific phosphatase (LYP) encoded by PTPN22.1, 2 In terms of the function of LYP, RNAi knockdown

of PTPN22 results in increased NF-_κ_B activity in the Jurkat T-cell line,2 and a targeted null allele of PTPN22 in mice is associated with enhanced activation of the T-cell receptor.5 Given

these data on LYP function, several lines of evidence suggest that the 620W allele of PTPN22 may lower the threshold of T-cell activation and hence may have a role in susceptibility to

inflammatory diseases.1, 2, 5 An association between the 620W allele and susceptibility to disease was first noted in subjects with Type 1 diabetes mellitus (T1D)1 and prompted us to assess

the possible role of the 620W allele in two other inflammatory diseases: Crohn's disease (CD) which affects the gastrointestinal tract and multiple sclerosis (MS) which consists of

inflammatory demyelinating episodes in the central nervous system. T cells play an important role in both CD and MS, suggesting a pathophysiological rationale for a possible role of PTPN22

620W in conferring susceptibility to these diseases.6, 7 Since the original report of association with T1D, additional associations have been described with susceptibility to rheumatoid

arthritis (RA),2 systemic lupus erythematosus (SLE),4 and autoimmune thyroiditis (AIT).8, 9 While it is possible that the 620W allele may be associated with susceptibility to several

different inflammatory diseases, an accurate estimate of the extent of the disease risk attributable to this allele awaits further replication efforts in each disease. Genetic data from some

linkage studies also suggested that the area of chromosome 1 in which PTPN22 is found (1p13) is contained in linkage peaks for CD10 and MS.11, 12, 13 However, 1p has not emerged

consistently as a risk locus for either disease. Furthermore, meta-analyses of linkage scans in each disease14, 15 and a recent high-density linkage scan in MS16 did not provide evidence for

a risk locus on 1p. These data suggest that an effect of PTPN22 620W on risk of MS or CD, if it exists, may be modest. A large sample of North American subjects of European ancestry with MS

was recently genotyped for the PTPN22 SNP, and this analysis revealed no statistically significant evidence that 620W was associated with susceptibility to MS.3 Since then, three other

small studies have provided further evidence that the 620W allele has little or no role in susceptibility to MS.9, 17, 18 One of these studies analyzed the sample collection of the multiple

autoimmune disease genetics consortium (MADGC)9 which also contains 40 cases of inflammatory bowel disease (a diagnostic category that includes patients with CD as well Ulcerative Colitis)

and reported no evidence for association of IBD with PTPN22 620W in this small sample. More recently, 455 CD cases from Canada19 and 146 CD20 cases from Germany failed to demonstrate

association between PTPN22 620W and CD. Our study extends these assessments and pools all available data to demonstrate that PTPN22 620W does not have a strong effect on susceptibility to

either CD or MS. MATERIALS AND METHODS SUBJECTS All affected MS subjects have a diagnosis of MS according to the Poser criteria21 and are of European descent. All individuals in the UK

cohort gave written informed consent for genetic analysis. The study has ethical approval from the Anglia and Oxford Multicentre Ethics Committee. All affected CD subjects fulfill clinical

criteria for CD22 and were consented using a common protocol approved by the institutional review boards of each institution contributing samples in Québec. This collection consists of 169

trios as well as an independent 249 subjects with CD and their 207 matched control subjects. No significant heterogeneity was noted between the allele frequencies in the two CD sample

collections or the novel and published MS collections. GENOTYTPING All samples were genotyped for rs2476601 using the Sequenom MassArray system as described previously.23 The genotyping

success rate was 97.3% for the MS samples and 93.0% for the CD samples. Genotypes did not deviate from Hardy–Weinberg Equilibrium (HWE; _P_-value >0.01). there was a Mendelian error (ME)

rate of 0.002 in the MS sample and 0 in the CD sample. STATISTICAL ANALYSIS ASSOCIATION TESTING Genetic association was assessed by the transmission disequilibrium test (TDT)24 for

collections consisting of trios, as implemented by GENEHUNTER.25 Association in cases and controls was determined by a standard χ2 test performed on a 2 × 2 contingency table. COMBINING

ANALYSES We computed a pooled estimate of the odds ratio (OR) using the logit method to combine data from different sources, and then derived a confidence interval for the OR as performed

for a single 2 × 2 table, as described previously.26 RESULTS In the 496 MS trios from the UK, the 620W allele frequency of 10% in the UK sample is similar to the reported allele frequency in

North American populations of European descent. 1, 2, 3, 4, 9 TDT analysis reveals that there is no evidence of association of the 620W allele in our MS samples, in fact, there is a

nominally significant undertransmission of this allele (Table 1, _P_=0.016). To derive a more accurate assessment of the role of this allele in MS using a family-based approach, we combined

our data with the MS trio data collected by Begovich _et al._3 The latter 582 North American MS trios of European ancestry from the UCSF collection represent the majority of the cases

reported by Begovich _et al_,3 and all cases fulfill McDonald criteria for MS.27 The combined collection of 877 MS trios of European ancestry demonstrates no association of MS susceptibility

with 620W (OR 0.84, 95% CI 0.66–1.06) (Table 1). To incorporate all extant data on PTPN22 in MS, we also performed a pooled analysis that combines all of the trio data as well as three

published case/control studies.9, 17, 18 This analysis also failed to demonstrate association of MS susceptibility with PTPN22 620W (OR 0.95, 95% CI 0.81–1.12) (Table 1). Finally, a recent

report suggests that the OR for an association of 620W with RA susceptibility in a large Swedish cohort is much greater in males (1.76) than females (1.19) (R. Plenge, personal

communication). We therefore stratified the pooled trio data by gender but saw no significant evidence of association with MS susceptibility with either gender (data not shown). To examine

subjects with CD, we genotyped 169 trios as well as 249 cases and 207 control subjects collected in the province of Québec, Canada. The minor allele frequency of 0.08 for 620W in the CD trio

samples is similar to those described in other populations of European descent,1, 2, 3, 4, 9, 17, 18 but the frequency of 0.04 in the case/control sample is less than expected. The combined

TDT and case/control analysis reveals no evidence of association of the 620W allele of PTPN22 with susceptibility for CD in our subject sample (OR 1.18, 95% CI 0.76–1.84) (Table 2). A

pooled analysis (Table 2) that combines our data with those of the other significant studies of PTPN22 in CD19, 20 similarly demonstrates no evidence of association between PTPN22 620W and

susceptibility to CD (OR 1.04, 95% CI 0.80–1.37). An analysis stratified by gender also did not reveal a significant association (data not shown). This pooled analysis of CD collections is

substantial, but, given the modest OR's associated with the PTPN22 620W allele in other diseases, this analysis should not be considered as definitive in the evaluation of the role of

PTPN22 in CD. DISCUSSION Reported estimates of the OR for 620W association with disease vary significantly from one study and one disease to another; however, an OR of 1.3 has clearly been

observed for this allele in certain SLE and RA studies4 (Plenge, personal communication). Taking the OR as a rough estimate of GRR, we therefore cannot rule out that the 620W allele is

associated with susceptibility to MS or CD. With the pooled MS sample of 1496 affected subjects, we have an estimated 89% power to exclude an OR >1.3 but only 59% power to exclude an OR

>1.2 (assuming a multiplicative model of disease risk, allele frequency of 0.1, and an _α_ of 0.05)(Genetic Power Calculator, http://statgen.iop.kcl.ac.uk/gpc/).28 Thus, it appears that

the PTPN22 620W allele does not have a strong effect on risk of MS. It is intriguing that the 496 trios from the UK genotyped as part of this study demonstrate a nominally significant

overtransmission of the major R620 allele. Given the lack of supporting evidence for this observations in the other studies3, 9, 17, 18 and the pooled analysis, this observation is likely to

represent a statistical fluctuation. However, since a detailed haplotype-based analysis of the PTPN22 gene has not yet been performed in subjects with MS, we cannot rule out the possibility

of allelic heterogeneity. An MS risk allele could exist and be in linkage disequilibrium with the PTPN22 R620 allele. The CD sample is smaller than the MS sample and has a somewhat lower

frequency of the 620W allele; therefore, we cannot exclude the possibility that PTPN22 has a modest effect on susceptibility to CD. With the pooled analysis of 1019 cases of CD, we have an

estimated 56% power to exclude an OR of 1.3 and 92% power to exclude an OR of 1.5 for the PTPN22 620W allele (assuming a multiplicative model of disease risk, allele frequency of 0.06, and

an _α_ of 0.05)(Genetic Power Calculator,http://statgen.iop.kcl.ac.uk/gpc/).28 Thus, while evidence mounts that the 620W allele of PTPN22 may have an effect on susceptibility to T1D, RA,

AIT, and SLE, the evidence so far points to a lack of association between this allele and susceptibility for either MS or CD. However, additional subjects from other collections will be

needed to definitively exclude a role for the 620W allele of PTPN22 in these diseases. REFERENCES * Bottini N, Musumeci L, Alonso A _et al_: A functional variant of lymphoid tyrosine

phosphatase is associated with type I diabetes. _Nat Genet_ 2004; 36: 337–338. Article  CAS  Google Scholar  * Begovich AB, Carlton VE, Honigberg LA _et al_: A missense single-nucleotide

polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. _Am J Hum Genet_ 2004; 75: 330–337. Article  CAS  Google Scholar  * Begovich

AB, Caillier SJ, Alexander HC _et al_: The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. _Am J Hum Genet_ 2005; 76: 184–187.

Article  CAS  Google Scholar  * Kyogoku C, Langefeld CD, Ortmann WA _et al_: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. _Am J Hum

Genet_ 2004; 75: 504–507. Article  CAS  Google Scholar  * Hasegawa K, Martin F, Huang G _et al_: PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells.

_Science_ 2004; 303: 685–689. Article  CAS  Google Scholar  * Wen Z, Fiocchi C : Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? _Clin Dev Immunol_ 2004; 11: 195–204.

Article  Google Scholar  * Hafler DA, Slavik JM, Anderson DE _et al_: Multiple sclerosis. _Immunol Rev_ 2005; 204: 208–231. Article  CAS  Google Scholar  * Smyth D, Cooper JD, Collins JE

_et al_: Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.

_Diabetes_ 2004; 53: 3020–3023. Article  CAS  Google Scholar  * Criswell LA, Pfeiffer KA, Lum RF _et al_: Analysis of families in the multiple autoimmune disease genetics consortium (MADGC)

collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. _Am J Hum Genet_ 2005; 76: 561–571. Article  CAS  Google Scholar  * Cho JH, Nicolae DL, Gold LH _et al_:

Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. _Proc Natl Acad Sci USA_ 1998; 95:

7502–7507. Article  CAS  Google Scholar  * Hensiek AE, Roxburgh R, Smilie B _et al_: Updated results of the United Kingdom linkage-based genome screen in multiple sclerosis. _J Neuroimmunol_

2003; 143: 25–30. Article  CAS  Google Scholar  * Dyment DA, Sadovnick AD, Willer CJ _et al_: An extended genome scan in 442 Canadian multiple sclerosis-affected sibships: a report from the

Canadian Collaborative Study Group. _Hum Mol Genet_ 2004; 13: 1005–1015. Article  CAS  Google Scholar  * Kenealy SJ, Babron MC, Bradford Y _et al_: A second-generation genomic screen for

multiple sclerosis. _Am J Hum Genet_ 2004; 75: 1070–1078. Article  CAS  Google Scholar  * van Heel DA, Fisher SA, Kirby A _et al_: Genome scan meta-analysis group of the IBD international

genetics consortium. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. _Hum Mol Genet_ 2004; 13: 763–770. Article  CAS 

Google Scholar  * GAMES; Transatlantic Multiple Sclerosis Genetics Cooperative: A meta-analysis of whole genome linkage screens in multiple sclerosis. _J Neuroimmunol_ 2003; 143: 39–46. *

Sawcer S, Ban M, Maranian M _et al_: A high-density screen for linkage in multiple sclerosis. _Am J Hum Genet_ 2005; 77: 454–467. Article  Google Scholar  * Matesanz F, Rueda B, Orozco G _et

al_: Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis. _J Neurol_ 2005; 252: 994–995. Article  CAS  Google Scholar  * Hinks A, Barton A, John S _et al_:

Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. _Arthritis Rheum_

2005; 52: 1694–1699. Article  CAS  Google Scholar  * van Oene M, Wintle RF, Liu X _et al_: Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not

Crohn's disease, in Canadian populations. _Arthritis Rheum_ 2005; 52: 1993–1998. Article  CAS  Google Scholar  * Wagenleiter SE, Klein W, Griga T _et al_: A case-control study of

tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease. _Int J Immunogenet_ 2005; 32: 323–324. Article  CAS  Google Scholar  * Poser CM, Paty DW, Scheinberg

L _et al_: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. _Ann Neurol_ 1983; 13: 227–231. Article  CAS  Google Scholar  * Lennard-Jones JE :

Classification of inflammatory bowel disease. _Scand J Gastroenterol_ 1989; 170: 2–6. Article  CAS  Google Scholar  * Vermeire S, Wild G, Kocher K _et al_: CARD15 genetic variation in a

Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. _Am J Hum Genet_ 2002; 71: 74–83. Article  CAS  Google Scholar  * Spielman RS, Ewens WJ : The TDT and

other family-based tests for linkage disequilibrium and association. _Am J Hum Genet_ 199; 59: 983–989. Google Scholar  * Daly MJ, Kruglyak L, Pratt S _et al_: GENEHUNTER 2.0-a complete

linkage analysis system. _Am J Hum Genet_ 1998; 63: S286. Google Scholar  * Morris JA, Gardner MJ : Calculating confidence intervals for relative risks (odds ratios) and standardised ratios

and rates. _Br Med J (Clin Res Ed)_ 1988; 296: 1313–1316. Article  CAS  Google Scholar  * McDonald WI, Compston A, Edan G _et al_: Recommended diagnostic criteria for multiple sclerosis:

guidelines from the International Panel on the diagnosis of multiple sclerosis. _Ann Neurol_ 2001; 50: 121–127. Article  CAS  Google Scholar  * Purcell S, Cherny SS, Sham PC : Genetic power

calculator: design of linkage and association genetic mapping studies of complex traits. _Bioinformatics_ 2003; 19: 149–150. Article  CAS  Google Scholar  Download references

ACKNOWLEDGEMENTS We thank Drs AB Begovich and J Oksenberg for sharing their genotyping data. PLD is the William C Fowler scholar in Multiple Sclerosis and is supported by an NINDS K08 grant

as well as the Clinical Investigator Training Program: Harvard-MIT Health Sciences and Technology Beth Israel Deaconess Medical Center, in collaboration with Pfizer Inc. JDR is supported by

grants from the NIDDK and the CCFA. The authors have no conflicts of interest to report. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurology, Center for Neurologic

Diseases, Brigham & Women's Hospital, and Harvard Medical School, Boston, MA, USA Philip L De Jager, Alicja Waliszewska, David A Hafler & John D Rioux * Broad Institute,

Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Philip L De Jager, Alicja Waliszewska, Lisa Farwell, David A Hafler & John D Rioux * University of

Cambridge Department of Clinical Neurosciences, Addenbrooke's, Hospital, Hills Road, Cambridge, UK Stephen Sawcer & Alastair Compston * Department of Gastroenterology, McGill

University Health Centre, McGill University, Montreal, Québec, Canada Gary Wild & Alain Bitton * Montreal Jewish General Hospital, Montreal, Québec, Canada Albert Cohen * Centre

Hospitalier Universitaire de Sherbrooke – Hotel-Dieu, Sherbrooke, Québec, Canada Diane Langelier Authors * Philip L De Jager View author publications You can also search for this author

inPubMed Google Scholar * Stephen Sawcer View author publications You can also search for this author inPubMed Google Scholar * Alicja Waliszewska View author publications You can also

search for this author inPubMed Google Scholar * Lisa Farwell View author publications You can also search for this author inPubMed Google Scholar * Gary Wild View author publications You

can also search for this author inPubMed Google Scholar * Albert Cohen View author publications You can also search for this author inPubMed Google Scholar * Diane Langelier View author

publications You can also search for this author inPubMed Google Scholar * Alain Bitton View author publications You can also search for this author inPubMed Google Scholar * Alastair

Compston View author publications You can also search for this author inPubMed Google Scholar * David A Hafler View author publications You can also search for this author inPubMed Google

Scholar * John D Rioux View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Philip L De Jager. RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE De Jager, P., Sawcer, S., Waliszewska, A. _et al._ Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22

in Crohn's disease and multiple sclerosis. _Eur J Hum Genet_ 14, 317–321 (2006). https://doi.org/10.1038/sj.ejhg.5201548 Download citation * Received: 12 July 2005 * Revised: 14

October 2005 * Accepted: 27 October 2005 * Published: 14 December 2005 * Issue Date: 01 March 2006 * DOI: https://doi.org/10.1038/sj.ejhg.5201548 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * multiple sclerosis * Crohn's disease * PTPN22 * association study